CZ298463B6 - Deriváty mocoviny pro použití jako inhibitory IMPDH enzymu a farmaceutické prostredky, které je obsahují - Google Patents

Deriváty mocoviny pro použití jako inhibitory IMPDH enzymu a farmaceutické prostredky, které je obsahují Download PDF

Info

Publication number
CZ298463B6
CZ298463B6 CZ0338098A CZ338098A CZ298463B6 CZ 298463 B6 CZ298463 B6 CZ 298463B6 CZ 0338098 A CZ0338098 A CZ 0338098A CZ 338098 A CZ338098 A CZ 338098A CZ 298463 B6 CZ298463 B6 CZ 298463B6
Authority
CZ
Czechia
Prior art keywords
group
nhc
urea derivative
methoxy
phenyl
Prior art date
Application number
CZ0338098A
Other languages
Czech (cs)
English (en)
Other versions
CZ338098A3 (cs
Inventor
M. Armistead@David
C. Badia@Michael
W. Bemis@Guy
S. Bethiel@Randy
A. Frank@Catharine
M. Novak@Perry
M. Ronkin@Steven
O. Saunders@Jeffrey
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/636,361 external-priority patent/US5807876A/en
Priority claimed from US08/832,165 external-priority patent/US6054472A/en
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of CZ338098A3 publication Critical patent/CZ338098A3/cs
Publication of CZ298463B6 publication Critical patent/CZ298463B6/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
CZ0338098A 1996-04-23 1997-04-21 Deriváty mocoviny pro použití jako inhibitory IMPDH enzymu a farmaceutické prostredky, které je obsahují CZ298463B6 (cs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/636,361 US5807876A (en) 1996-04-23 1996-04-23 Inhibitors of IMPDH enzyme
US08/801,780 US6344465B1 (en) 1996-04-23 1997-02-14 Inhibitors of IMPDH enzyme
US08/832,165 US6054472A (en) 1996-04-23 1997-04-02 Inhibitors of IMPDH enzyme

Publications (2)

Publication Number Publication Date
CZ338098A3 CZ338098A3 (cs) 1999-02-17
CZ298463B6 true CZ298463B6 (cs) 2007-10-10

Family

ID=27417590

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ0338098A CZ298463B6 (cs) 1996-04-23 1997-04-21 Deriváty mocoviny pro použití jako inhibitory IMPDH enzymu a farmaceutické prostredky, které je obsahují

Country Status (21)

Country Link
US (3) US6541496B1 (enEXAMPLES)
EP (1) EP0902782A1 (enEXAMPLES)
CN (2) CN1515248A (enEXAMPLES)
AP (1) AP813A (enEXAMPLES)
AU (1) AU723730B2 (enEXAMPLES)
BG (1) BG64507B1 (enEXAMPLES)
BR (1) BR9708735A (enEXAMPLES)
CA (1) CA2252465C (enEXAMPLES)
CZ (1) CZ298463B6 (enEXAMPLES)
EA (1) EA004771B1 (enEXAMPLES)
HU (1) HUP0004421A3 (enEXAMPLES)
ID (1) ID16664A (enEXAMPLES)
IL (1) IL126674A (enEXAMPLES)
IN (1) IN190508B (enEXAMPLES)
NO (1) NO312963B1 (enEXAMPLES)
NZ (1) NZ332405A (enEXAMPLES)
OA (1) OA10902A (enEXAMPLES)
PL (1) PL192628B1 (enEXAMPLES)
SK (1) SK286662B6 (enEXAMPLES)
TR (1) TR199802136T2 (enEXAMPLES)
WO (1) WO1997040028A1 (enEXAMPLES)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301802B6 (cs) * 1999-03-19 2010-06-30 Vertex Pharmaceuticals Incorporated Deriváty mocoviny jako inhibitory IMPDH a farmaceutické prostredky s jejich obsahem

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4080541B2 (ja) * 1996-10-18 2008-04-23 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子
WO1998024785A1 (en) * 1996-12-02 1998-06-11 Fujisawa Pharmaceutical Co., Ltd. Indole-urea derivatives with 5-ht antagonist properties
EP1366766A1 (en) * 1997-03-14 2003-12-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
EP1027328B1 (en) * 1997-10-31 2006-08-23 Aventis Pharma Limited Substituted anilides
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
ATE300299T1 (de) * 1997-12-22 2005-08-15 Bayer Pharmaceuticals Corp Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
ATE346600T1 (de) * 1997-12-22 2006-12-15 Bayer Pharmaceuticals Corp Inhibierung der p38 kinase-aktivität durch die verwendung von aryl- und heteroarylsubstituierten harnstoffen
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
WO1999055663A1 (en) * 1998-04-29 1999-11-04 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
WO1999062869A1 (fr) * 1998-06-04 1999-12-09 Kumiai Chemical Industry Co., Ltd. Derives de phenylacetylene et bactericides a usage agricole ou horticole
CN1263733C (zh) * 1998-10-22 2006-07-12 神经研究公司 取代苯基衍生物,它们的制备和用途
AU1707700A (en) 1998-10-29 2000-05-22 Bristol-Myers Squibb Company Novel inhibitors of impdh enzyme
US6596747B2 (en) 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
US6420403B1 (en) 1998-10-29 2002-07-16 Edwin J. Iwanowicz Inhibitors of IMPDH enzyme
AU764479B2 (en) 1998-10-29 2003-08-21 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
RU2233269C2 (ru) * 1998-11-02 2004-07-27 Авентис Фарма Лимитед Замещенные анилиды, фармацевтическая композиция и способ лечения
US6262090B1 (en) 1998-12-09 2001-07-17 American Home Products Corporation Aminopyridine-containing thiourea inhibitors of herpes viruses
ATE267824T1 (de) * 1998-12-09 2004-06-15 Wyeth Corp Alpha-methylbenzyl-enthaltende thioharnstoffe als inhibitoren von herpes-viren mit einer phenylenediamingruppe
US6166028A (en) 1998-12-09 2000-12-26 American Home Products Corporation Diaminopuridine-containing thiourea inhibitors of herpes viruses
US6201013B1 (en) 1998-12-09 2001-03-13 American Home Products Corporation Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group
IL143262A0 (en) * 1998-12-09 2002-04-21 American Home Prod Thiourea inhibitors of herpes viruses
US6337338B1 (en) 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
WO2000037434A1 (fr) * 1998-12-22 2000-06-29 Mitsubishi Chemical Corporation Derives d'amide
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
SK12832001A3 (sk) * 1999-03-12 2002-01-07 Boehringer Ingelheim Pharmaceuticals, Inc. Protizápalové látky, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
WO2000073288A1 (en) * 1999-05-28 2000-12-07 Vertex Pharmaceuticals Incorporated Method for preparing 5-substituted oxazoles
US6107052A (en) * 1999-06-09 2000-08-22 Roche Diagnostics Corporation Enzymatic measurement of mycophenolic acid
WO2001000622A1 (en) * 1999-06-25 2001-01-04 Vertex Pharmaceuticals Incorporated Prodrugs of carbamate inhibitors of impdh
JP2001011059A (ja) * 1999-06-28 2001-01-16 Nippon Synthetic Chem Ind Co Ltd:The 5−(2−置換−4−ニトロフェニル)−オキサゾールの製造方法
JP2001011060A (ja) * 1999-06-28 2001-01-16 Nippon Synthetic Chem Ind Co Ltd:The 新規オキサゾール化合物及びその製造方法
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
US6867299B2 (en) 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
WO2001081340A2 (en) * 2000-04-24 2001-11-01 Bristol-Myers Squibb Company Heterocycles that are inhibitors of impdh enzyme
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6423849B1 (en) 2000-09-01 2002-07-23 The Nippon Synthetic Chemical Industry Co., Ltd. Process of preparing 5-(2-substituted-4-nitrophenyl)-oxazole, novel oxazole compound, and process of preparing the same
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US6593362B2 (en) * 2001-05-21 2003-07-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
CA2475818C (en) 2002-02-11 2011-07-19 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
EP1402887A1 (en) * 2002-09-18 2004-03-31 Jerini AG New compounds for the inhibition of undesired cell proliferation and use thereof
JP4789621B2 (ja) 2002-12-06 2011-10-12 バーテックス ファーマシューティカルズ インコーポレイテッド ジフェニルUraIMPDHインヒビターおよびアポトーシス誘導性抗癌剤を含む組成物
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US7220768B2 (en) * 2003-02-11 2007-05-22 Wyeth Holdings Corp. Isoxazole-containing thiourea inhibitors useful for treatment of varicella zoster virus
WO2005000284A2 (en) 2003-05-20 2005-01-06 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
TWI359147B (en) * 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
AU2004282148A1 (en) 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incoporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
JP4890254B2 (ja) * 2003-10-27 2012-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド Hcvns3−ns4aプロテアーゼ耐性突然変異体
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
CN1938332B (zh) 2004-02-04 2011-10-19 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
US7317030B2 (en) 2004-02-26 2008-01-08 4Sc Ag Compounds as inhibitors of cell proliferation and viral infections
EP1568696A1 (en) * 2004-02-26 2005-08-31 4Sc Ag Compounds as inhibitors of cell proliferation and viral infections
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
CA2576297C (en) 2004-08-12 2011-01-25 Pfizer Inc. Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
SG191661A1 (en) * 2004-10-01 2013-07-31 Vertex Pharma Hcv ns3-ns4a protease inhibition
TW201424733A (zh) 2004-10-29 2014-07-01 Vertex Pharma 劑量型式
WO2006076592A1 (en) * 2005-01-14 2006-07-20 Cgi Pharmaceuticals, Inc. 1,3 substituted diaryl ureas as modulators of kinase activity
ES2393741T3 (es) * 2005-01-14 2012-12-27 Gilead Connecticut, Inc. Ureas 1,3-diarilsustituidas como moduladores de la actividad quinasa
EP1917010A2 (en) * 2005-02-08 2008-05-07 Aspreva Pharmaceuticals SA Compositions and methods for treating vascular, autoimmune and inflammatory diseases
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
PL1868579T3 (pl) 2005-03-07 2011-03-31 Bayer Healthcare Llc Kompozycja farmaceutyczna zawierająca difenylomocznik podstawiony omega-karboksyarylem do leczenia nowotworu
US7777040B2 (en) * 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
EP1879858A2 (en) 2005-05-09 2008-01-23 Vertex Pharmaceuticals, Inc. Processes for preparing biaryl ureas and analogs thereof
US7605270B2 (en) * 2005-05-09 2009-10-20 Vertex Pharmaceuticals Incorporated Polymorphic forms of (S).-tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) benzylcarbamate
WO2007014920A1 (en) 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
US7666834B2 (en) 2005-07-29 2010-02-23 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis C virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
ME01318B (me) 2005-07-29 2013-12-20 Tibotec Pharm Ltd Makrociklički inhibitori virusa hepatitisa C
PL1913015T3 (pl) 2005-07-29 2014-04-30 Janssen R&D Ireland Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
DE602006019741D1 (de) 2005-07-29 2011-03-03 Medivir Ab Makrocyclische inhibitoren des hepatitis-c-virus
TWI393723B (zh) 2005-07-29 2013-04-21 Tibotec Pharm Ltd C型肝炎病毒之大環抑制劑(九)
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
MX2008001528A (es) 2005-08-02 2008-04-04 Vertex Pharma Inhibidores de serina proteasas.
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP2392588A3 (en) 2005-11-11 2012-03-07 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
JP5436864B2 (ja) 2006-02-27 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド Vx−950を含む共結晶体およびそれを含む医薬組成物
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
BRPI0710878A2 (pt) 2006-04-11 2015-03-31 Novartis Ag Compostos orgânicos e seus usos
JP2010504362A (ja) * 2006-09-25 2010-02-12 アレテ セラピューティクス, インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
WO2008040778A2 (en) 2006-10-04 2008-04-10 Tibotec Pharmaceuticals Ltd. Carboxamide 4-[(4-pyridyl)amino] pyrimidines for the treatment of hepatitis c
CL2007003299A1 (es) 2006-11-17 2008-08-22 Tibotec Pharm Ltd Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
EP2134717A2 (en) * 2007-02-27 2009-12-23 Vertex Pharmceuticals Incorporated Inhibitors of serine proteases
PT2114924E (pt) * 2007-02-27 2012-04-03 Vertex Pharma Co-cristais e composições farmacêuticas que compreendem os mesmos
JP2010524974A (ja) * 2007-04-20 2010-07-22 デシファラ ファーマスーティカルズ, エルエルシー 骨髄増殖性疾患および他の増殖性疾患の治療に有用なキナーゼ阻害剤
MX2009011930A (es) 2007-05-04 2009-11-18 Vertex Pharma Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c.
EP2185546B1 (en) * 2007-08-30 2011-10-26 Vertex Pharmceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US8524716B2 (en) 2007-12-24 2013-09-03 Janssen R&D Ireland Macrocyclic indoles as hepatitis C virus inhibitors
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作c型肝炎病毒抑制劑之巨環吲哚衍生物
CN102124012B (zh) 2008-08-14 2014-07-02 泰博特克药品公司 可作为丙型肝炎病毒抑制剂的大环吲哚衍生物
PE20150939A1 (es) 2008-12-03 2015-07-19 Presidio Pharmaceuticals Inc Inhibidores de la proteina no estructural 5a del virus de la hepatitis c
WO2010065668A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
JP2012517478A (ja) 2009-02-12 2012-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、hcv組合せ治療剤
EP2408753A4 (en) * 2009-03-20 2012-11-07 Univ Brandeis COMPOUNDS AND METHOD FOR THE TREATMENT OF MICROBIAL STOMACH DARM INFECTIONS IN MAMMALS
JP5735482B2 (ja) 2009-03-27 2015-06-17 プレシディオ ファーマシューティカルズ インコーポレイテッド 縮合環のc型肝炎阻害剤
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
WO2011094489A1 (en) 2010-01-29 2011-08-04 Vertex Pharmaceuticals Incorporated Therapies for treating hepatitis c virus infection
WO2011112516A1 (en) 2010-03-08 2011-09-15 Ico Therapeutics Inc. Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
WO2011149856A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
NZ604040A (en) 2010-06-03 2015-02-27 Pharmacyclics Inc The use of inhibitors of bruton’s tyrosine kinase (btk)
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
MX2012015198A (es) 2010-06-24 2013-02-11 Janssen R & D Ireland Preparacion de acido 13-ciclohexil-3-metoxi-6-[metil-(2-{2-[metil- (sulfamoil)-amino]-etoxi}-etil)-carbomoil]-7h-indolo-[2,1-a]-[2]- benzazepin-10-carboxilico.
US20120014912A1 (en) 2010-07-14 2012-01-19 Vertex Pharmaceuticals Incorporated Palatable pharmaceutical composition
WO2012020036A1 (en) 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Hepatitis c virus inhibitors
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
CN102985104A (zh) 2011-02-25 2013-03-20 麦德托尼克公司 在干扰素-α治疗方案中使用药代动力学分布和药效动力学分布的方法和系统
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
CN103732242A (zh) 2011-06-23 2014-04-16 迪格纳生物技术公司 用与IFN-α2b组合的IFN-α5在患者群体中治疗慢性丙型肝炎
WO2012175581A1 (en) 2011-06-24 2012-12-27 F. Hoffmann-La Roche Ag Antiviral compounds
KR101621181B1 (ko) 2011-10-10 2016-05-13 에프. 호프만-라 로슈 아게 항바이러스성 화합물
KR20140104030A (ko) 2011-12-16 2014-08-27 에프. 호프만-라 로슈 아게 Hcv ns5a의 억제제
CN104011060A (zh) 2011-12-20 2014-08-27 弗·哈夫曼-拉罗切有限公司 作为hcv rna复制抑制剂的4‘-叠氮基,3’-氟取代的核苷衍生物
MY171577A (en) 2011-12-20 2019-10-21 Hoffmann La Roche 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
ES2558608T3 (es) 2011-12-28 2016-02-05 Janssen Sciences Ireland Uc Derivados hetero-bicíclicos como inhibidores del VHC
WO2013116339A1 (en) 2012-01-31 2013-08-08 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
CA2857262A1 (en) 2012-02-24 2013-08-29 F. Hoffmann-La Roche Ag Antiviral compounds
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
WO2014028931A2 (en) 2012-08-17 2014-02-20 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
BR112015017414A2 (pt) 2013-01-23 2017-07-11 Hoffmann La Roche derivados de triazol antivirais
EP2964637B1 (en) 2013-03-05 2017-04-12 F. Hoffmann-La Roche AG Antiviral compounds
CA2912682C (en) 2013-05-16 2021-07-06 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives
SG11201509427RA (en) 2013-05-16 2015-12-30 Riboscience Llc 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
JP6508785B2 (ja) 2013-10-25 2019-05-08 ファーマサイクリックス エルエルシー ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
EP3684374B1 (en) 2017-09-21 2025-07-30 Riboscience LLC 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
EP3746060A1 (en) 2018-01-31 2020-12-09 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of mastocytosis
JP2021512105A (ja) 2018-01-31 2021-05-13 デシフェラ・ファーマシューティカルズ,エルエルシー 消化管間質腫瘍の治療のための併用療法
CA3094324A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
CN109970675A (zh) * 2018-05-28 2019-07-05 中国医学科学院医药生物技术研究所 一组硫脲化合物及其制备方法和应用
CN112313237A (zh) 2018-06-19 2021-02-02 诺华股份有限公司 N-取代的四氢噻吩并吡啶衍生物及其用途
US12098117B2 (en) * 2018-12-11 2024-09-24 Duke University Compositions and methods for the treatment of cancer
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
CA3150433A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
CN110590535A (zh) * 2019-10-12 2019-12-20 重庆医药高等专科学校 用二氧化硒氧化芳香乙酮制备芳香乙醛酸的方法
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
CN118948773A (zh) 2019-12-30 2024-11-15 德西费拉制药有限责任公司 1-(4溴-5-(1乙基-7-(甲氨基)-2侧氧基-1,2-二氢-1,6-萘啶-3基)-2氟苯基)-3-苯基脲的组合物
WO2021189018A1 (en) 2020-03-20 2021-09-23 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405644A (en) * 1979-07-14 1983-09-20 Bayer Aktiengesellschaft Medicaments for the treatment of disorders of lipometabolism and their use
US5380879A (en) * 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171904A (en) 1965-10-21 1969-11-26 Unilever Ltd Anilinobenzimidazoles having Antibacterial Properties
CA985286A (en) 1971-05-04 1976-03-09 Charles J. Paget (Jr.) (substituted anilino) benzoxazoles useful in the prophylaxis of mareks disease
US5283257A (en) 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
WO1994012184A1 (en) 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
US5444072A (en) 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405644A (en) * 1979-07-14 1983-09-20 Bayer Aktiengesellschaft Medicaments for the treatment of disorders of lipometabolism and their use
US5380879A (en) * 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301802B6 (cs) * 1999-03-19 2010-06-30 Vertex Pharmaceuticals Incorporated Deriváty mocoviny jako inhibitory IMPDH a farmaceutické prostredky s jejich obsahem

Also Published As

Publication number Publication date
CZ338098A3 (cs) 1999-02-17
PL329639A1 (en) 1999-04-12
US20050282876A1 (en) 2005-12-22
BG102945A (en) 1999-08-31
CN1116288C (zh) 2003-07-30
EA199800943A1 (ru) 1999-04-29
HUP0004421A3 (en) 2002-10-28
AU2678597A (en) 1997-11-12
US7329681B2 (en) 2008-02-12
IN190508B (enEXAMPLES) 2003-08-02
NO984917L (no) 1998-12-23
US6541496B1 (en) 2003-04-01
NO312963B1 (no) 2002-07-22
NO984917D0 (no) 1998-10-22
NZ332405A (en) 2000-06-23
HUP0004421A2 (hu) 2001-04-28
CA2252465A1 (en) 1997-10-30
SK286662B6 (sk) 2009-03-05
EA004771B1 (ru) 2004-08-26
CN1219929A (zh) 1999-06-16
OA10902A (en) 2001-10-11
ID16664A (id) 1997-10-30
US6967214B2 (en) 2005-11-22
PL192628B1 (pl) 2006-11-30
BG64507B1 (bg) 2005-05-31
BR9708735A (pt) 1999-08-03
SK146198A3 (en) 1999-07-12
EP0902782A1 (en) 1999-03-24
AP813A (en) 2000-02-28
WO1997040028A1 (en) 1997-10-30
AP9700973A0 (en) 1997-07-31
TR199802136T2 (xx) 2001-06-21
IL126674A (en) 2005-08-31
IL126674A0 (en) 1999-08-17
AU723730B2 (en) 2000-09-07
US20030195202A1 (en) 2003-10-16
CA2252465C (en) 2007-07-03
CN1515248A (zh) 2004-07-28

Similar Documents

Publication Publication Date Title
CZ298463B6 (cs) Deriváty mocoviny pro použití jako inhibitory IMPDH enzymu a farmaceutické prostredky, které je obsahují
US6344465B1 (en) Inhibitors of IMPDH enzyme
US6054472A (en) Inhibitors of IMPDH enzyme
US6518291B1 (en) Inhibitors of IMPDH enzyme
US6653309B1 (en) Inhibitors of IMPDH enzyme technical field of the invention
US20020111378A1 (en) Inhibitors of IMPDH enzyme
EP1076641A1 (en) Inhibitors of impdh enzyme
US5932600A (en) Inhibitors of IMPDH enzyme
KR100643057B1 (ko) Impdh효소억제제로서의우레아유도체
EP1366766A1 (en) Inhibitors of IMPDH enzyme
MXPA98008804A (en) Im enzyme inhibitors

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20110421